{
    "organizations": [],
    "uuid": "38a2e1926dca1317a42675a009aa1834c7baaab5",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-marinus-pharmaceuticals-provides-b/brief-marinus-pharmaceuticals-provides-business-update-and-2017-financial-results-idUSASB0C8XZ",
    "ord_in_thread": 0,
    "title": "BRIEF-Marinus Pharmaceuticals Provides Business Update And 2017 Financial Results",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 6 (Reuters) - Marinus Pharmaceuticals Inc:\n* MARINUS PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND 2017 FINANCIAL RESULTS\n* MARINUS - ‍EXPECTS TO INITIATE A GLOBAL, PIVOTAL STUDY IN CDKL5 DEFICIENCY DISORDER IN MID-2018​\n* MARINUS PHARMACEUTICALS - ‍ BELIEVE CASH, CASH EQUIVALENTS AS OF DEC 31, 2017 TO ENABLE FUNDING OPERATING EXPENSES AND CAPEX NEEDS INTO 2020​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-06T20:43:00.000+02:00",
    "crawled": "2018-03-07T19:20:44.023+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "marinus",
        "pharmaceutical",
        "inc",
        "marinus",
        "pharmaceutical",
        "provides",
        "business",
        "update",
        "financial",
        "result",
        "marinus",
        "initiate",
        "global",
        "pivotal",
        "study",
        "cdkl5",
        "deficiency",
        "disorder",
        "marinus",
        "pharmaceutical",
        "believe",
        "cash",
        "cash",
        "equivalent",
        "dec",
        "enable",
        "funding",
        "operating",
        "expense",
        "capex",
        "need",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}